84 related articles for article (PubMed ID: 2046344)
1. Urinary screening for midazolam and its major metabolites with the Abbott ADx and TDx analyzers and the EMIT d.a.u. benzodiazepine assay with confirmation by GC/MS.
Fraser AD; Bryan W; Isner AF
J Anal Toxicol; 1991; 15(1):8-12. PubMed ID: 2046344
[TBL] [Abstract][Full Text] [Related]
2. Urinary screening for alprazolam and its major metabolites by the Abbott ADx and TDx analyzers with confirmation by GC/MS.
Fraser AD; Bryan W; Isner AF
J Anal Toxicol; 1991; 15(1):25-9. PubMed ID: 2046338
[TBL] [Abstract][Full Text] [Related]
3. Urinary screening for alpha-OH triazolam by FPIA and EIA with confirmation by GC/MS.
Fraser AD; Bryan W; Isner AF
J Anal Toxicol; 1992; 16(6):347-50. PubMed ID: 1293398
[TBL] [Abstract][Full Text] [Related]
4. Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC.
Fraser AD; Isner AF; Bryan W
J Anal Toxicol; 1993; 17(7):427-31. PubMed ID: 8309217
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Abbott ADx and TDx serum benzodiazepine immunoassays for analysis of alprazolam.
Fraser AD; Bryan W
J Anal Toxicol; 1991; 15(2):63-5. PubMed ID: 1675703
[TBL] [Abstract][Full Text] [Related]
6. New fluorescence polarization immunoassays for analysis of barbiturates and benzodiazepines in serum and urine: performance characteristics.
Schwenzer KS; Pearlman R; Tsilimidos M; Salamone SJ; Cannon RC; Wong SH; Gock SB; Jentzen JJ
J Anal Toxicol; 2000; 24(8):726-32. PubMed ID: 11110029
[TBL] [Abstract][Full Text] [Related]
7. Urinary screening for alprazolam, triazolam, and their metabolites with the EMIT d.a.u. benzodiazepine metabolite assay.
Fraser AD
J Anal Toxicol; 1987; 11(6):263-6. PubMed ID: 3323671
[TBL] [Abstract][Full Text] [Related]
8. Identification of urinary benzodiazepines and their metabolites: comparison of automated HPLC and GC-MS after immunoassay screening of clinical specimens.
Valentine JL; Middleton R; Sparks C
J Anal Toxicol; 1996 Oct; 20(6):416-24. PubMed ID: 8889678
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Abbott ADx Amphetamine/Methamphetamine II abused drug assay: comparison to TDx, EMIT, and GC/MS methods.
Przekop MA; Manno JE; Kunsman GW; Cockerham KR; Manno BR
J Anal Toxicol; 1991; 15(6):323-6. PubMed ID: 1779660
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values.
Fraser AD; Meatherall R
J Anal Toxicol; 1996; 20(4):217-23. PubMed ID: 8835658
[TBL] [Abstract][Full Text] [Related]
11. Abbott phencyclidine and barbiturates abused drug assays: evaluation and comparison of ADx FPIA, TDx FPIA, EMIT, and GC/MS methods.
Caplan YH; Levine B
J Anal Toxicol; 1989; 13(5):289-92. PubMed ID: 2693834
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fluorescence polarization immunoassay, enzyme immunoassay, and thin-layer chromatography for urine cannabinoid screening. Effects of analyte adsorption and vigorous mixing of specimen on detectability.
Dextraze P; Griffiths WC; Camara P; Audette L; Rosner M
Ann Clin Lab Sci; 1989; 19(2):133-8. PubMed ID: 2546480
[TBL] [Abstract][Full Text] [Related]
13. Application of the Syva EMIT and Abbott TDx amphetamine immunoassays to the detection of 3,4-methylene-dioxymethamphetamine (MDMA) and 3,4-methylene-dioxyethamphetamine (MDEA) in urine.
Kunsman GW; Manno JE; Cockerham KR; Manno BR
J Anal Toxicol; 1990; 14(3):149-53. PubMed ID: 1973747
[TBL] [Abstract][Full Text] [Related]
14. Benzodiazepines identified by capillary gas chromatography-mass spectrometry, with specific ion screening used to detect benzophenone derivatives.
Jones CE; Wians FH; Martinez LA; Merritt GJ
Clin Chem; 1989 Jul; 35(7):1394-8. PubMed ID: 2667799
[TBL] [Abstract][Full Text] [Related]
15. Investigation into some aspects of EMIT d.a.u., TLC, and GC-MS urinalysis of bromazepam.
El-Haj BM; Al-Amri AM; Hassan MH; Bin-Khadem RK
J Anal Toxicol; 2001; 25(5):316-22. PubMed ID: 11499884
[TBL] [Abstract][Full Text] [Related]
16. Immunoassay detection of benzodiazepines and benzodiazepine metabolites in blood.
Huang W; Moody DE
J Anal Toxicol; 1995 Oct; 19(6):333-42. PubMed ID: 8926726
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of TDx cocaine metabolite assay.
Poklis A
J Anal Toxicol; 1987; 11(5):228-30. PubMed ID: 3682784
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion profiles of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-THC: cannabinoid metabolites to creatinine ratio study IV.
Fraser AD; Worth D
Forensic Sci Int; 2004 Jul; 143(2-3):147-52. PubMed ID: 15240035
[TBL] [Abstract][Full Text] [Related]
19. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
Dixon RB; Floyd D; Dasgupta A
Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
[TBL] [Abstract][Full Text] [Related]
20. Abbott propoxyphene assay: evaluation and comparison of TDx FPIA and GC/MS methods.
Kintz P; Mangin P
J Anal Toxicol; 1993; 17(4):222-4. PubMed ID: 8371551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
